Literature DB >> 34294400

Feasibility of Coronary Access in Patients With Acute Coronary Syndrome and Previous TAVR.

Won-Keun Kim1, Costanza Pellegrini2, Sebastian Ludwig3, Helge Möllmann4, Florian Leuschner5, Raj Makkar6, Jürgen Leick7, Ignacio J Amat-Santos8, Oliver Dörr9, Philipp Breitbart10, Victor A Jimenez Diaz11, Maciej Dabrowski12, Tanja Rudolph13, Pablo Avanzas14, Jatinderjit Kaur15, Stefan Toggweiler16, Sebastian Kerber17, Patrick Ranosch17, Damiano Regazzoli18, Derk Frank19, Uri Landes20, John Webb21, Marco Barbanti22, Paola Purita23, Thomas Pilgrim24, Branislav Liska25, Noriaki Tabata26, Tobias Rheude2, Moritz Seiffert3, Clemens Eckel4, Abdelhakim Allali15, Roberto Valvo22, Sung-Han Yoon6, Nikos Werner7, Holger Nef27, Yeong-Hoon Choi28, Christian W Hamm27, Jan-Malte Sinning26.   

Abstract

OBJECTIVES: The aim of this study was to characterize the feasibility of coronary angiography (CA) and percutaneous coronary intervention (PCI) in acute settings among patients who have undergone transcatheter aortic valve replacement (TAVR).
BACKGROUND: Impaired coronary access after TAVR may be challenging and particularly in acute settings could have deleterious consequences.
METHODS: In this international registry, data from patients with prior TAVR requiring urgent or emergent CA were retrospectively collected. A total of 449 patients from 25 sites with acute coronary syndromes (89.1%) and other acute cardiovascular situations (10.9%) were included.
RESULTS: Success rates were high for CA of the right coronary artery (98.3%) and left coronary artery (99.3%) and were higher among patients with short stent-frame prostheses (SFPs) than in those with long SFPs for CA of the right coronary artery (99.6% vs 95.9%; P = 0.005) but not for CA of the left coronary artery (99.7% vs 98.7%; P = 0.24). PCI of native coronary arteries was successful in 91.4% of cases and independent of valve type (short SFP 90.4% vs long SFP 93.4%; P = 0.44). Guide engagement failed in 6 patients, of whom 3 underwent emergent coronary artery bypass grafting and another 3 died in the hospital. Among patients requiring revascularization of native vessels, independent predictors of 30-day all-cause mortality were prior diabetes, cardiogenic shock, and failed PCI but not valve type or success of coronary engagement.
CONCLUSIONS: CA or PCI after TAVR in acute settings is usually successful, but selective coronary engagement may be more challenging in the presence of long SFPs. Among patients requiring PCI, prior diabetes, cardiogenic shock, and failed PCI were predictors of early mortality.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PCI; TAVR; coronary access; myocardial infarction

Year:  2021        PMID: 34294400     DOI: 10.1016/j.jcin.2021.05.007

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  3 in total

Review 1.  Evolving Indications of Transcatheter Aortic Valve Replacement-Where Are We Now, and Where Are We Going.

Authors:  Jules Mesnier; Vassili Panagides; Jorge Nuche; Josep Rodés-Cabau
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

2.  Procedural Safety and Device Performance of the Portico™ Valve from Experienced TAVI Centers: 30-Day Outcomes in the Multicenter CONFIDENCE Registry.

Authors:  Helge Mollmann; Axel Linke; Luis Nombela-Franco; Martin Sluka; Juan Francisco Oteo Dominguez; Matteo Montorfano; Won-Keun Kim; Martin Arnold; Mariuca Vasa-Nicotera; Lenard Conradi; Anthony Camuglia; Francesco Bedogni; Ganesh Manoharan
Journal:  J Clin Med       Date:  2022-08-18       Impact factor: 4.964

3.  Coronary access following ACURATE neo implantation for transcatheter aortic valve-in-valve implantation: Ex vivo analysis in patient-specific anatomies.

Authors:  Arif A Khokhar; Francesco Ponticelli; Adriana Zlahoda-Huzior; Kailash Chandra; Rossella Ruggiero; Marco Toselli; Francesco Gallo; Alberto Cereda; Alessandro Sticchi; Alessandra Laricchia; Damiano Regazzoli; Antonio Mangieri; Bernhard Reimers; Simone Biscaglia; Carlo Tumscitz; Gianluca Campo; Ghada W Mikhail; Won-Keun Kim; Antonio Colombo; Dariusz Dudek; Francesco Giannini
Journal:  Front Cardiovasc Med       Date:  2022-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.